SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Jun 27, 2007 - Annals of
Internal Medicine has published the results of a two-year clinical
study on the impact of genistein on bone loss. The paper, "Effects
of the Phytoestrogen Genistein on Bone Metabolism in Osteopenic
Postmenopausal Women-A Randomized Trial," appears in the current
issue (June 19, 2007) and details the safety and efficacy of
genistein for the dietary management of osteopenia and
osteoporosis. The paper reports a significant gain in bone density
among patients taking genistein at both 12 and 24 months over both
baseline and placebo.
Key study findings include:
-- Over 85 percent of the women in the study taking genistein
showed a gain in bone density.
-- Patients taking genistein in addition to calcium and vitamin
D showed a gain in bone density of approximately 3 percent per year
over baseline and 6 percent per year over those taking the
placebo.
-- No adverse events were reported in the study. All
participants were monitored for vasomotor symptoms, vaginal
bleeding, breast tenderness, endometrial thickness, depression,
irritability, insomnia, and gastrointestinal (GI) symptoms, as well
as for changes in hematologic, renal and liver function tests. No
changes were noted in any of these parameters except for mild GI
symptoms.
Patients in the test group of the study used 54 mg/day of highly
purified genistein isolated from soy along with calcium and vitamin
D. Principle Investigator for the study, Francesco Squadrito, M.D.,
Professor of Pharmacology and Head of Clinical Pharmacology, School
of Medicine, University of Messina, Italy, explains that there were
some interesting aspects to the study: "The placebo in this study
was not an inactive pill; instead it was the current standard of
care for osteopenia - calcium plus vitamin D. Unlike other research
in this area, this study was controlled for soy intake and
additional supplem
'"/>
Page: 1 2 3 Related medicine technology :1.
Chi-Med Announces Positive Phase II Proof-of-Concept Data for
HMPL-004 in Ulcerative Colitis2.
Opexa Advances Monocyte Derived Islet Technology to Proof of
Principle in stz-induced NOD/SCID Mice3.
Phosphagenics Announces Positive Proof of Concept Results from
Studies Utilizing Companys Dermal Drug Delivery Technology4.
Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line
Results with ...5.
Evotec Reports Positive Proof-of-Concept Top-Line Results with
Insomnia Drug Candidate EVT 2016.
POZEN Announces Positive Outcome for PA 325 Proof of Concept Study7.
Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis8.
YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial9.
New Phase 3 Study Published in The Lancet Evaluates Efficacy and
Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination
Therapy in Treatment-Experienced Adults With HIV10.
Advanced Life Sciences Announces Supplemental Efficacy Data from
First Pivotal Phase 3 Pneumonia Clinical Trial11.
Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix
Provides Excellent Protection Against Lesions Caused by Most Common
Cancer-Causing Virus Types